MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities
Rhea-AI Summary
Renalytix (NASDAQ:RNLXY) has partnered with MVP Health Care to expand access to its FDA-approved kidneyintelX.dkd™ test for diabetic kidney disease patients across MVP's Northeast network. The collaboration aims to improve early detection and management of kidney disease in patients with type 2 diabetes.
The partnership will make the innovative diagnostic test available to all MVP customers in New York, including Medicare and Medicaid beneficiaries. The test is recommended by KDIGO, the international clinical guideline organization for kidney disease, and has shown measurable improvements in patient outcomes and quality metrics where implemented.
Positive
- FDA-approved kidneyintelX.dkd test will be available to all MVP customers, including Medicare/Medicaid beneficiaries
- Partnership expands market reach in the Northeast region
- Test demonstrates measurable improvements in patient outcomes and HEDIS measures
- Endorsement by KDIGO (international clinical guideline organization)
Negative
- None.
News Market Reaction – RNLXY
In the trading session that priced this news, RNLXY declined 2.78%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities.
Through this partnership, MVP Health Care and Renalytix will collaborate with physician groups across MVP's network to introduce and implement the kidneyintelX.dkd™ FDA-approved test. By making this innovative technology more accessible to providers and patients, the partnership supports earlier intervention, more personalized care plans, and healthier, more independent lives.
"At MVP Health Care, we are committed to delivering innovative, affordable solutions that improve access to care and support better health for our members," said MVP Health Care's President, Dr. Richard Dal Col. "This partnership with Renalytix reflects our mission to empower both providers and patients with the tools they need to make informed, proactive decisions about their health care journey. For our customers living with type 2 diabetes and CKD, this means earlier insights, more personalized support, and a better path forward."
The kidneyintelX.dkd™ test will be available to all MVP customers in
"Forward-thinking in its approach, MVP Health Care is bringing together the right partners to address the growing and costly CKD epidemic," said James McCullough, CEO of Renalytix. "Where kidneyintelX.dkd is in use, we are seeing measurable improvements in patient outcomes and quality metrics, including HEDIS measures for blood pressure and HbA1c control in high-risk populations. We're proud to work alongside MVP to make this level of care more widely available."
To learn more about Renalytix, visit renalytix.com, and for information about the kidneyintelX.dkd test, visit kidneyintelx.com.
About Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in
About MVP Health Care
MVP Health Care is a nationally recognized, not-for-profit health insurer caring for members in
For further information, please contact:
Renalytix plc | |
View original content:https://www.prnewswire.com/news-releases/mvp-health-care-and-renalytix-partner-to-bring-life-changing-kidney-disease-testing-to-local-communities-302509197.html
SOURCE Renalytix plc